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Abstract
Background: If conservative treatment for chronic plantar fasciitis fails, often a corticosteroid injection is given. 
Corticosteroid injection gives temporarily pain reduction, but no healing. Blood platelets initiate the natural healing 
rate. GPS® gives an eightfold concentrate platelets of patients own blood. Injection of these platelets in the attachment 
of the fascia to the os calcis might induce a healing rate.
Methods and design: A randomized controlled multi centre trial will be performed. The study population consists of 
120 patients of 18 years and older. Patients with chronic plantar fasciitis will be allocated randomly to have a steroid 
injection or an autologous platelet concentrate injections. Data will be collected before the procedure, 4,8,12,26 weeks 
and 1 year after the procedure.
The main outcome measures of this study are pain and function measured with questionnaires.
Conclusion: Recent literature show positive effects for the treatment of tendinosis with autologous platelet injections. 
The forthcoming trial will compare treatment for chronic plantar fasciitis with a steroid injection versus an autologous 
platelet injection. Our results will be published as soon as they become available.
Trial Registration: Trial registration number: http://www.clinicaltrials.gov NCT00758641.
Background
Chronic plantar fasciitis is the most common cause of
foot complaints in the United States, making up 11 to
15% of the foot symptoms requiring professional care
among adults [1,2]. The incidence of plantar fasciitis
peaks in people between the ages of 40 to 60 years with
no bias towards either sex [3].
The underlying condition that causes plantar fasciitis is
a degenerative tissue condition that occurs near the site
of origin of the plantar fascia at the medial tuberosity of
the calcaneous [4]. In acute cases, plantar fasciitis is char-
acterized by classical signs of inflammation including
pain, swelling and loss of function. For more chronic con-
ditions, however, inflammation is not the underlying tis-
sue disruption. In fact, histology of chronic cases has
shown no signs of inflammatory cell invasion into the
affected area [5]. The tissue instead is characterized his-
tologically by infiltration with macrophages, lympho-
cytes, and plasma cells; tissue destruction; and repair
involving immature vascularization and fibrosis [5]. The
normal fascia tissue is replaced by an angiofibroblastic
hyperplastic tissue which spreads itself throughout the
surrounding tissue creating a self-perpetuating cycle of
degeneration [5]. Numerous methods have been advo-
cated for treating plantar fasciitis, including rest, non-
steroidal anti-inflammatory medication, night splints,
foot orthosis, stretching protocols and extracorporeal
shock wave therapy. Steroid injections are a popular
method of treating the condition but only seem to be use-
ful in the short term and only to a small degree [6]. Other
various types of surgical procedures have also been rec-
ommended [2,7-11]. The use of corticosteroids is particu-
larly troubling as several studies have linked plantar fascia
rupture to repeated local injections of a corticosteroid
[2,11-13]. When neither rest and neither activity restric-
tion nor conservative treatments result in a satisfactory * Correspondence: t.gosens@elisabeth.nl
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outcome, the patient is often interested in treatment
options other than surgery.
In an animal model the addition of growth factors to
the ruptured tendon has been shown to increase the heal-
ing of the tendon [14,15]. In humans it has been shown
that the injection of whole blood into the tendon
decreases the pain [16].
PRP is promoted as an ideal autologous biological
blood-derived product, which can be exogenously
applied to various tissues where it releases high concen-
trations of platelet derived growth factors that enhance
wound healing, bone healing and also tendon healing. In
addition PRP possesses antimicrobial properties that may
contribute to the prevention of infections [17]. When
platelets become activated, growth factors are released
and initiate the body's natural healing response.
We will evaluating the effects of PRP injections on "self-
reported function and pain" in a double-blind random-
ized trial.
Methods and design
Study design
Randomization will be performed after patients are
deemed eligible and have provided informed consent.
Patients will be randomly allocated to the concentrated
autologous platelet group (PRP group) or to the corticos-
teroid group (control group). A computer using block
randomisation of 10 patients will be used to create a ran-
domization schedule. Treatment assignments (placed in
sequentially numbered opaque envelopes) will be
assigned by the trial managers (WL, HS, HH, TG) who
will also arrange the facilities needed for the procedure.
All patients with a plantar fasciitis who are admitted to
one of the participating hospitals and meet the inclusion
criteria are asked to join the study.
Plantar fasciitis was defined as pain at the point of the
fascia plantaris origin at direct palpation. All affected
patients were screened with X-ray of the calcaneus for
bony abnormalities and to difentiate for subtalar arthritis.
Sonography and MRI were not used standardly.
The Medical Ethical Committee of The Netherlands
approved the study design, procedures and informed
consent.
Trial registration number: http://www.clinicaltrials.gov
NCT00758641.
Study population
The study will be conducted at the Orthopaedic Depart-
ments of the HAGA Ziekenhuis Den Haag, St. Antonius
Ziekenhuis Nieuwegein, Diaconessenhuis Leiden and St.
Elisabeth Ziekenhuis Tilburg between November 2008
and December 2010. Authors JP and TG will be responsi-
ble for the data and safety monitoring. Inclusion criteria:
patients aged > 18 years, with plantar fasciitis (6-12
months duration), who failed conservative treatment are
included. They have to be able to understand the
informed consent and have a VAS pain score in the
morning by first steps higher as 5 (0-10 scale).
P a t i e n t s  w i l l  b e  e x c l u d e d  f r o m  t h e  s t u d y  w h e n  t h e y
received local steroid injections within 6 months, physi-
cal/occupational therapies within 4 weeks, or non-steroi-
dal anti-inflammatory within 1 week prior to
randomization. Also patients will be excluded with the
inability to fulfil follow-up criteria, significant cardiovas-
cular, renal or hepatic disease, pregnancy, (local) malig-
nancy, history of amenia (hemoglobin < 5.0), previous
surgery for plantar fasciitis, active bilateral plantar fascii-
tis, diagnosis of vascular insufficiency or neuropathy
related to heel pain, hypothyroidism and diabetics.
Intervention
Platelet Concentrate Preparation
Fifty-five milliliters whole blood is collected from the
uninvolved arm into a 60-mL syringe that contained 5 mL
sodium citrate. A peripheral complete blood count is also
collected at the time of the initial blood draw. The blood
is then prepared according to the GPS System instruc-
tions (Cell Factor Technologies, Warsaw, Ind). This
device is a desktop-size centrifuge with disposable cylin-
ders for the blood approximately 0.05cc Platelet concen-
trate is obtained for each patient.
Autologous platelet concentrate contains concentrated
white blood cells and platelets that are suspended in
plasma. Since an acidic anticoagulant is introduced to the
whole blood used to produce the platelet concentrate, the
platelet concentrate must be buffered to increase the pH
to normal physiologic levels. This is accomplished with
8.4% sodium bicarbonate solution added at a ratio 0.05cc
of sodium bicarbonate solution to 1 cc of platelet concen-
trate.
The resulting buffered platelet concentrate contains
approximately a 6 to 8 times concentration of platelets
compared to baseline whole blood. No activating agent is
used. The total time from blood draw to injection in the
patients is about 30 minutes. No specialized equipment,
other than the GPS machine, is required.
Injection Technique
Initially, bupivacaine is infiltrated into the skin and sub-
cutaneous tissue of both groups as a local field block.
Approximately 0.05cc is also injected directly into the
area of maximum tenderness. Then, either 5 to 6 cc plate-
let concentrate or 5 to 6cc corticosteroid is injected using
a 22-g needle into the plantar fasciitis using a peppering
technique. This technique involved a single skin portal
and then 5 penetrations of the fascia.
Post-procedure Protocol
Immediately after the injection, the patient is kept in sit-
ting position without moving the foot for 15 minutes.Peerbooms et al. BMC Musculoskeletal Disorders 2010, 11:69
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Patients will go to the physiotherapist to obtain stretching
exercises. Patients are sent home with instructions to
limit their use of the feet for approximately 48 hours and
use hydrocodone or acetaminophen for pain. The use of
nonsteroidal medication is prohibited. After 48 hours,
patients are given a standardized stretching protocol to
follow for 2 weeks. A formal strengthening program is
initiated after this stretching. At 4 weeks after the proce-
dure, patients are allowed to proceed with normal sport-
ing or recreational activities as tolerated. Any type of foot
orthoses will not be allowed.
The corticosteroid
The type of steroid that is used during the study is kena-
cort 40 mg/ml triamcinolon acetonide.
Study parameters/endpoints
Main study pain
Pain will be measured using a visual analogous scale at all
time points. The VAS score of the Foot Function Index
will be used.
The score records the patient's reported pain using a
scale of 0-10, where 0 is pain-free and 10 is the worst pain
imaginable. The scale will be a 10 centimeter line begin-
ning with 0 and ending with 10, the score will be marked
at the point on the line that corresponds with the patient
response.
Each patient randomly assigned to a treatment and
with at least one non-missing pre- and post-baseline
measurement, will be classified at each visit, as either a
treatment success or failure. Patients with a score reduc-
tion of 25% compared to baseline, did not require pain
medication beyond the protocol defined allowable
period, and did not require escape therapy will be consid-
ered a treatment success.
The absolute change from baseline to endpoint means
the baseline value is subtracted from the endpoint value.
Percent change is defined as the absolute change multi-
plied by 100 divided by the baseline value. For patients
whose pain improves, these values will be less than zero.
The treatment is defined as successful if the pain reduc-
tion after 6 months is over 25%. If the patient is lost to fol-
low-up, the last measurement will be carried forward. If
the patient has obtained a different treatment, the subject
is classified as unsuccessful.
Function and quality of life
The function and satisfaction will be measured using the
AOFAS foot questionnaire [18,19], the Foot Function
Index (FFI) [20-22] and WHOQOL quality of life ques-
tionnaire [23,24] questionnaires.
Follow up
All patients will be followed up at 4, 8, 12, 26 and 52
weeks. All patients will complete AOFAS and VAS scores
at all follow up moments
Determination of sample size
This study has two main parameters: number of patients
with 25% pain reduction after 6 months and the average
pain reduction;
Corticosteroids and stretching have a recurrence of
pain after 6 months [2,25]. Previous studies with platelet
rich plasma by tendonitis showed that the platelet rich
plasma group has no recurrence. These results showed 63
percent success rate (VAS reduction over 25 percent after
6 months) for the platelet rich plasma group compared to
27 percent success rate for the corticosteroid group. If
these percentages are comparable for plantar fasciitis 38
patients are needed in all groups to achieve a 25% pain
reduction (alfa 0,05 and power 0,9).
Conservative treatment with taping or stretching shows
a 30 ± 24 points decrease in VAS pain at walking [26,27].
Corticosteroid injections have shown to have comparable
results [2,25]. 25% increase in pain reduction is seen as
clinical relevant. To prove a difference in pain reduction
of 15 ± 24 points and a α of 0,05 and a power of 0,9, 55
patients are needed in each group.
Needed number of patients
To be able to measure a difference in average pain reduc-
tion, the largest number of patient is needed 55 patients
in both groups. To compensate for possible lost to follow-
up, 60 patients will be included in each group (Figure 1).
Statistical analysis
This is a double blind randomized and prospective study.
Patients will be randomized in equal proportions to
either autologous platelet concentrate or corticosteroid
injections. The primary endpoint of the trial is treatment
Figure 1 Flow chart.
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success at 6 months. The other measurements are to
measure the speed of recovery and the re-occurrence of
pain.
Statistical analyses will test the null hypotheses of no
differences between patients treated with autologous
platelet concentrate and those treated with corticosteroid
in the proportion of the protocol defined, successfully
treated patients.
All tests of treatment effect will be made using a one-
sided alpha level of 0.025, unless otherwise specified.
Tests for the interaction between treatment and a block-
ing factor will be made at the alpha level of 0.10. All p-val-
ues will be rounded then quoted to 3 decimal places,
unless the true p-value is less than 0.001 whereby the
notation (p < .001) will be used or if the true p-value is
greater than 0.999, in which case the notation (p > .999)
will be used. Confidence intervals, where indicated for
the difference between the two treatment groups, will be
calculated at the 95% level. All data will be analyzed by a
blinded researcher.
Discussion
This randomized study is designed to test the use of con-
centrated autologous platelets in patients with plantar
fasciitis. Plantar fasciitis is a common problem with many
available treatment methods. When conservative treat-
ment results in a non-satisfactory outcome, the patient is
often interested in treatment options other than surgery.
Steroid injections are a popular method of treating the
condition but only seem to be useful in the short term
and only to a small degree [6]. Treatment with corticos-
teroids has a high frequency of relapse and recurrence,
probably because intra fascial injection may lead to per-
manent adverse changes within the structure of the fascia
and because patients tend to overuse the foot after injec-
tion as a result of direct pain relief [28].
In a recent study of Peerbooms et al. [29] a positive
effect of injection of PRP in the common extension origin
for lateral epicondylitis was seen. This report describes
the first comparison of an autologous platelet concentrate
with corticosteroid injection as a treatment for lateral
epicondylitis in patients who have failed non-operative
treatment. It demonstrates that a single injection of con-
centrated autologous platelets improves pain and func-
tion more than corticosteroid injection. These
improvements were sustained over time with no reported
complications [29].
The injection of platelet-rich-plasma (PRP) into the
effected tissue addresses the healing stages necessary to
reverse the degenerative process which are going on in
the base of the plantar fascia. The individual cytokines
present in the platelet α-granules have been shown to
enhance fibroblast migration and proliferation, up-regu-
late vascularization, and increases collagen deposition in
a variety of in vitro and in vivo settings [30]. The cytok-
ines present in platelet α-granules have been shown to
affect the healing stages necessary to reverse a chronic
plantar fasciitis condition [30]. Additionally, many of
these cytokines have been seen to work in a dose depen-
dent manner [30].
The treatment of tendinosis with an injection of con-
centrated autologous platelets may be a nonoperative
alternative. Utilising the Recover system the patient's own
platelets can be collected into a highly concentrated for-
mula. This treatment concept directly addresses the
existing condition and should prove to be a superior
alternative to current conservative treatments for chronic
plantar fasciitis.
We postulate that the concentrated growth factors
work in a synergetic manner to initiate a tendon healing
response. This hypothesis is supported by in vitro
research in the literature. Transforming growth factor β1
is shown to significantly increase type I collagen produc-
tion by tendon sheath fibroblasts. This same mechanism
is likely to be active in chronic plantar fasciitis [31].
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